Arterys Raises $28 Million to Accelerate the Delivery of Medical AI to Practices Around the World
San Francisco, CA -- Arterys, a leading global medical imaging platform to deliver clinical AI products over the internet, just received its seventh USA FDA clearance and announced its latest round of funding — a $28 million Series C investment from a syndicate led by Benslie Investment Group and Temasek Holdings, with participation by Fosun, Revelation Partners, Emergent Medical Partners, and Varian Medical Systems.
Arterys said it will deploy this new round of financing to broaden the Arterys ecosystem, comprising a broad set of partners on the new Arterys Marketplace working together to deliver clinical applications built on the Arterys cloud-native viewer and platform. A particular focus will be to accelerate partners’ efforts to bring new clinical-grade AI applications to providers by extending its proprietary technology platform to application partners thereby making it easier for clinicians to integrate AI into their workflows from a single interface.
“The current crisis has shown us the necessity of a different approach to providing healthcare, where technology and AI are crucial for future success. Arterys is committed to transforming the way AI is integrated into the medical workflow, a promise that is long due in the industry. We recently launched our cloud platform and marketplace that will consolidate the work of thousands of AI models to be readily available for use by healthcare institutions around the globe,” said Henry Weinstein, Managing Partner at Benslie International Ltd.
Arterys has appointed John Axerio-Cilies, co-founder, as the acting CEO. “We realize that we can’t transform the healthcare system alone,” says Axerio-Cilies. “No company can. And now, the same technology and strengths that we’ve leveraged to build our core products [Arterys Cardio AI and Arterys Lung AI] are now available to medical innovators at companies and universities around the world — they can benefit from regulatory support, channel partnerships, performance, security, and best-in-class hospital system integrations.”
Interested in bringing a unified AI experience to your practice? Start today by reaching out to John Axerio-Cilies via info@arterys.com.
Related news
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol “DXR” after the transfer. The Company’s common stock will continue to trade on the NYSE American until the...
-
The Indoor Microbiome and Its Impact on Indoor Environmental Quality
Last year, the U.S. Environmental Protection Agency (EPA) announced the release of a new webpage to provide information about the indoor microbiome. All of the living microorganisms inside of an indoor environment, and their by-products, are collectively known as the indoor microbiome. The indoor microbiome that surrounds each of us is diverse and dynamic, made up of bacteria, viruses, fungi and other single-celled organisms. These microorganisms may be growing or inactive, and may be present in different life...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress with BVA-100® next generation development. The presentation will be available on-demand beginning at 7:00 a.m. ET...
-
Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic. Dr. Jan Bakker, MD,...
-
Daxor Awarded New Patent for Blood Volume Guidance Technology to Improve Treatment & Outcomes
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways. “We are very excited to receive this patent, which covers key innovations in the use of blood volume analysis to optimally guide fluid...
Customer comments
No comments were found for Arterys Raises $28 Million to Accelerate the Delivery of Medical AI to Practices Around the World. Be the first to comment!